Learn how ACR staff and volunteers support the interests of the rheumatology community in public policy efforts related to Medicare reimbursement, step therapy reform, drug pricing, supporting the medical workforce and more.
From Oct. 15–Nov. 15, all donations to RheumPAC will be amplified by matching contributions, so it’s the best time to make your yearly investment. Donors above the silver level will be invited to a special event at ACR Convergence 2023.
In late September, 80 rheumatologists, rheumatology professionals and patients living with rheumatic disease convened in Washington, D.C., for the ACR’s annual Advocates for Arthritis conference, where they marshaled in support of legislation that would reduce current barriers to care for patients.
Two ACR-led resolutions on in-office specialty drug dispensing and the proposed NIH Public Access Plan passed the House of Delegates and will become AMA policy.
The Tennessee Rheumatology Society is helping rheumatology professionals in the state keep pace with a rapidly growing population by supporting both current practitioners and fellows in the state’s two rheumatology fellowship programs.
After significant pushback from the AMA, ACR and other medical societies, Cigna has delayed implementation of changes to its modifier 25 reimbursement policy, originally scheduled to take effect May 25.
The ACR will co-lead with the American Society of Clinical Oncology a resolution on in-office dispensing of specialty drugs and will lead 10 other specialty societies to advance a resolution on the proposed NIH Public Access Plan and equitable access to quality clinical research.
This legislative season has seen key pharmacy benefit manager reforms but slow movement on other issues, such as copay accumulators and utilization management. The ACR is also monitoring emerging topics, such as biomarker testing and post-public health emergency telehealth reforms.
Nearly 70 rheumatologists and rheumatology professionals convened in Washington, D.C., to advocate on behalf of legislation that would preserve and help to grow America’s healthcare workforce.
In April, the Medicare Payment Advisory Committee voted to recommend a change in the add-on payment for Part B drugs, including reducing payment for more expensive drugs. The ACR sent a letter to MedPAC expressing concerns about the significant impacts such policies would have on rheumatologists.